warfarin

• all-cause mortality

  no effect, RR 0.94, 95% CI 0.33-2.67

  Two studies reported on the risk of death, finding no difference between NPP and UMC (RR = 0.94; 95% CI 0.33 to 2.67, I2 = 0%).

  PMID:40456519 · one of two readings recorded this

• death

  no effect, RR 0.94, 95% CI 0.33 to 2.67

  Two studies reported on the risk of death, finding no difference between NPP and UMC (RR = 0.94; 95% CI 0.33 to 2.67, I2 = 0%).

  PMID:40456519 · one of two readings recorded this

• hemorrhage

  no effect, RR 1.07, 95% CI 0.44 to 2.63

  There was no significant difference in the risk of hemorrhage between NPP and UMC when combining results from the 5 studies reporting this outcome (RR = 1.07; 95% CI 0.44 to 2.63, I2 = 0%).

  PMID:40456519 · both readings recorded this

• patient satisfaction

  no effect, SMD 0.56, 95% CI -0.04 to 1.15

  There was a non-significant higher patient satisfaction in the NPP group compared to UMC in the 3 studies reporting this outcome (standardized mean difference [SMD] 0.56; 95% CI -0.04 to 1.15, I2 = 85%).

  PMID:40456519 · both readings recorded this

• time in therapeutic range (TTR) for ambulatory warfarin management

  no effect, MD 1.64%, 95% CI -1.86 to 5.16

  Not recorded as a finding: the comparison was against another active treatment

  There was no significant difference in TTR (mean difference [MD] 1.64%; 95% confidence interval [CI]-1.86 to 5.16, I2 = 0%) between NPP and UMC.

  PMID:40456519 · one of two readings recorded this

• time in therapeutic range (TTR)

  no effect, MD 1.64%, 95% CI -1.86 to 5.16

  There was no significant difference in TTR (mean difference [MD] 1.64%; 95% confidence interval [CI]-1.86 to 5.16, I2 = 0%) between NPP and UMC.

  PMID:40456519 · both readings recorded this

• time spent in therapeutic range (TTR), warfarin management by non-physician providers vs usual medical care

  no effect, MD 1.64%, 95% CI -1.86 to 5.16

  Not recorded as a finding: the comparison was against another active treatment

  There was no significant difference in TTR (mean difference [MD] 1.64%; 95% confidence interval [CI]-1.86 to 5.16, I2 = 0%) between NPP and UMC.

  PMID:40456519 · one of two readings recorded this

• bleeding incidence rate

  n = 18

  The incidence rate of bleeding in our cohort was 5.3 per 100 patient-years (95% confidence interval [95%CI] 1.4–13.6)

  PMID:40879863 · one of two readings recorded this

• creatinine at baseline

  n = 18

  Creatinine – Mean and SD | 0.95 ± 0.31 mg/dl

  PMID:40879863 · one of two readings recorded this

• DOAC as first line of treatment

  n = 18

  DOAC as first line of treatment (%) | 27.8

  PMID:40879863 · one of two readings recorded this

• haemoglobin at baseline

  n = 18

  Haemoglobin – Mean and SD | 13.2 ± 1.67 g/dl

  PMID:40879863 · one of two readings recorded this

• mean follow-up duration

  n = 18

  The mean follow-up was 50.1 ± 24.1 months

  PMID:40879863 · one of two readings recorded this

• patients previously on vitamin K antagonist

  n = 18

  Previous therapy with VKA (%) | 72.2

  PMID:40879863 · one of two readings recorded this

• recurrent VTE and other thrombotic events

  no effect, n = 18

  During the observation period, no VTE relapses or other thrombotic events were recorded

  PMID:40879863 · one of two readings recorded this

• total bleeding events

  n = 18

  Of the total of 4 bleeding events occurred during follow-up, two were major bleeding events

  PMID:40879863 · one of two readings recorded this

• all-cause mortality

  Several studies have shown a trend toward lower all-cause mortality among patients assigned to NOACs, particularly among patients with a low bleeding risk profile.

  PMID:41222886 · one of two readings recorded this

• all-cause mortality (secondary outcome)

  unclear

  Several studies have shown a trend toward lower all-cause mortality among patients assigned to NOACs, particularly among patients with a low bleeding risk profile.

  PMID:41222886 · one of two readings recorded this

• major bleeding after aortic bioprosthetic valve replacement, pooled hazard ratio

  increases, HR 1.22, 95% CI: 0.88–1.68, p = 0.22

  Not recorded as a finding: the comparison was against another active treatment

  Compared with warfarin, NOACs may increase the risk of major bleeding (HR 1.22, 95% CI: 0.88–1.68, p = 0.22, I² = 72.4%).

  PMID:41222886 · one of two readings recorded this

• major bleeding

  HR 1.22, 95% CI 0.88-1.68, p = 0.22

  Compared with warfarin, NOACs may increase the risk of major bleeding (HR 1.22, 95% CI: 0.88–1.68, p = 0.22, I² = 72.4%).

  PMID:41222886 · both readings recorded this

• minor bleeding events

  no effect

  However, it is important to note that in the studies that reported minor bleeding, the incidence of these events was similar between the two anticoagulants.

  PMID:41222886 · one of two readings recorded this

• thromboembolic events (arterial thromboembolism, stroke, MI, valve thrombosis, systemic embolism, DVT, PE, TIA)

  HR 0.91, 95% CI 0.76-1.09, p = 0.31

  The pooled results from these studies revealed that the NOAC cohort had a slight reduction in thromboembolic events compared with the warfarin cohort (HR 0.91, 95% CI: 0.76–1.09, p = 0.31, I² = 40.8%).

  PMID:41222886 · one of two readings recorded this

• thromboembolic events (arterial thromboembolism, stroke, myocardial infarction, symptomatic valve thrombosis, systemic embolism, DVT, PE, TIA, intracardiac/bioprosthesis thrombosis), pooled hazard ratio

  HR 0.91, 95% CI 0.76-1.09, p = 0.31

  Not recorded as a finding: the comparison was against another active treatment

  The pooled results from these studies revealed that the NOAC cohort had a slight reduction in thromboembolic events compared with the warfarin cohort (HR 0.91, 95% CI: 0.76–1.09, p = 0.31, I² = 40.8%).

  PMID:41222886 · one of two readings recorded this

• thromboembolic events

  no effect, HR 0.91, 95% CI: 0.76–1.09, p = 0.31

  The pooled results from these studies revealed that the NOAC cohort had a slight reduction in thromboembolic events compared with the warfarin cohort (HR 0.91, 95% CI: 0.76–1.09, p = 0.31, I² = 40.8%).

  PMID:41222886 · one of two readings recorded this

• baseline INR (median)

  no effect, p = 0.233

  Baseline INR | 1.1 | (1.00–1.16) | 1.1 | (1.02–1.17) | 0.233a

  PMID:41528716 · one of two readings recorded this

• day of the first INR assessment (median)

  decreases, p = 0.001

  Day of the first INR assessment | 7.0 | (5.00–9.00) | 4.0 | (4.00–4.00) | < 0.001a

  PMID:41528716 · one of two readings recorded this

• first INR value (median)

  increases, p = 0.001

  First INR value | 1.4 | (1.13–1.91) | 1.7 | (1.32–2.24) | < 0.001a

  PMID:41528716 · one of two readings recorded this

• number of dose adjustments prior to first therapeutic INR (median)

  decreases, p = 0.003

  Number of Dose Adjustments Prior First Therapeutic INR | 2.0 | (0.00–3.00) | 1.0 | (0.00–2.00) | 0.003a

  PMID:41528716 · one of two readings recorded this

• plan after first INR visit: increase dose (n)

  decreases, p = 0.001

  Increase dose | 250 | (49.9) | 88 | (31.5) | < 0.001b

  PMID:41528716 · one of two readings recorded this

• plan after first INR visit: loading dose (n)

  decreases, p = 0.005

  Loading dose | 18 | (3.6) | 1 | (0.4) | 0.005b

  PMID:41528716 · one of two readings recorded this

• plan after first INR visit: maintain dose (n)

  no effect, p = 0.075

  Maintain dose | 183 | (36.5) | 120 | (43.0) | 0.075b

  PMID:41528716 · one of two readings recorded this

• plan after first INR visit: reduce dose (n)

  increases, p = 0.003

  Reduce dose | 61 | (12.2) | 56 | (20.1) | 0.003b

  PMID:41528716 · one of two readings recorded this

• plan after first INR visit: withhold dose (n)

  no effect, p = 0.149

  Withhold dose | 25 | (5.0) | 21 | (7.5) | 0.149b

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 255

  Within 0–12 Months | 694 | -0.600 | < 0.001 | 0.416 | 439 | -0.653 | < 0.001 | 0.488 | 255 | -0.513 | < 0.001 | 0.290

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 263

  Within 0–3 Months | 739 | -0.658 | < 0.001 | 0.361 | 476 | -0.680 | < 0.001 | 0.382 | 263 | -0.615 | < 0.001 | 0.315

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 260

  Within 0–6 Months | 721 | -0.710 | < 0.001 | 0.500 | 461 | -0.755 | < 0.001 | 0.533 | 260 | -0.620 | < 0.001 | 0.435

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 439

  Within 0–12 Months | 694 | -0.600 | < 0.001 | 0.416 | 439 | -0.653 | < 0.001 | 0.488 | 255 | -0.513 | < 0.001 | 0.290

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 476

  Within 0–3 Months | 739 | -0.658 | < 0.001 | 0.361 | 476 | -0.680 | < 0.001 | 0.382 | 263 | -0.615 | < 0.001 | 0.315

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 461

  Within 0–6 Months | 721 | -0.710 | < 0.001 | 0.500 | 461 | -0.755 | < 0.001 | 0.533 | 260 | -0.620 | < 0.001 | 0.435

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 694

  Within 0–12 Months | 694 | -0.600 | < 0.001 | 0.416 | 439 | -0.653 | < 0.001 | 0.488 | 255 | -0.513 | < 0.001 | 0.290

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 739

  Within 0–3 Months | 739 | -0.658 | < 0.001 | 0.361 | 476 | -0.680 | < 0.001 | 0.382 | 263 | -0.615 | < 0.001 | 0.315

  PMID:41528716 · one of two readings recorded this

• Spearman correlation of TTR with time to INR stabilization

  decreases, p = 0.001, n = 721

  Within 0–6 Months | 721 | -0.710 | < 0.001 | 0.500 | 461 | -0.755 | < 0.001 | 0.533 | 260 | -0.620 | < 0.001 | 0.435

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-12 months, adjusted (GLM)

  no effect, p = 0.66

  0–12 Months | 63.3 | (1.04) | 63.9 | (1.35) | 0.717 | 65.7 | (5.19) | 64.8 | (4.99) | 0.660a

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-12 months, crude

  no effect, p = 0.717

  0–12 Months | 63.3 | (1.04) | 63.9 | (1.35) | 0.717 | 65.7 | (5.19) | 64.8 | (4.99) | 0.660a

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-3 months, adjusted (GLM)

  no effect, p = 0.709

  0–3 Months | 49.4 | (1.33) | 52.4 | (1.79) | 0.183 | 45.9 | (6.73) | 45.0 | (6.48) | 0.709a

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-3 months, crude

  no effect, p = 0.183

  0–3 Months | 49.4 | (1.33) | 52.4 | (1.79) | 0.183 | 45.9 | (6.73) | 45.0 | (6.48) | 0.709a

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-6 months, adjusted (GLM)

  no effect, p = 0.721

  0–6 Months | 55.2 | (1.23) | 58.1 | (1.64) | 0.160 | 59.8 | (6.16) | 58.9 | (5.94) | 0.721a

  PMID:41528716 · one of two readings recorded this

• time in therapeutic range 0-6 months, crude

  no effect, p = 0.16

  0–6 Months | 55.2 | (1.23) | 58.1 | (1.64) | 0.160 | 59.8 | (6.16) | 58.9 | (5.94) | 0.721a

  PMID:41528716 · one of two readings recorded this

• time to INR stabilization, adjusted (GLM)

  no effect, p = 0.248

  Total Days to Achieve INR Stabilization | 138.6 | (4.41) | 111.8 | (5.93) | < 0.001 | 104.1 | (22.43) | 94.1 | (21.55) | 0.248a

  PMID:41528716 · one of two readings recorded this

• time to INR stabilization, crude

  decreases, p = 0.001

  Total Days to Achieve INR Stabilization | 138.6 | (4.41) | 111.8 | (5.93) | < 0.001 | 104.1 | (22.43) | 94.1 | (21.55) | 0.248a

  PMID:41528716 · one of two readings recorded this

• total days to achieve first therapeutic INR (median)

  decreases, p = 0.001

  Total Days to Achieve First Therapeutic INR | 30.0 | (14.00–61.80) | 14.0 | (6.80–38.30) | < 0.001a

  PMID:41528716 · one of two readings recorded this

• total warfarin dose per week to reach first therapeutic INR (median)

  increases, p = 0.021

  Total Warfarin Dose/Week to Reach First Therapeutic INR | 17.5 | (14.00–24.50) | 21.0 | (14.00–24.50) | 0.021a

  PMID:41528716 · one of two readings recorded this

• TTR by quartile of time to INR stabilization

  Patients in the fastest quartile (Quartile 1: < 55 days) achieved the highest TTR (80.6%)

  PMID:41528716 · one of two readings recorded this

• TTR by quartile of time to INR stabilization

  followed by Quartile 2 (55–97 days, 73.6%)

  PMID:41528716 · one of two readings recorded this

• TTR by quartile of time to INR stabilization

  Quartile 3 (98–181 days, 66.4%)

  PMID:41528716 · one of two readings recorded this

• TTR by quartile of time to INR stabilization

  decreases, p = 0.001

  the slowest quartile (Q4: > 182 days) with the lowest TTR (47.3%) (p < 0.001)

  PMID:41528716 · one of two readings recorded this

• all-cause mortality

  decreases, p = 0.001

  DOACs (aHR, 0.57; 95% CI, 0.43–0.78; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• all-cause mortality

  decreases, p = 0.001

  Both warfarin (IPTW aHR, 0.53; 95% CI, 0.38–0.74; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• all-cause mortality

  no effect, p = 0.667

  All-cause mortality was similar between DOACs and warfarin (IPTW aHR, 1.09 [0.75–1.58]; p = 0.667)

  PMID:41531219 · one of two readings recorded this

• gastrointestinal bleeding

  no effect, p = 0.134

  a similar risk of GIB (IPTW aHR, 1.33; 95% CI, 0.92–1.94; p = 0.134)

  PMID:41531219 · one of two readings recorded this

• gastrointestinal bleeding

  increases, p = 0.001

  GIB (IPTW aHR, 1.82; 95% CI, 1.27–2.63; p = 0.001)

  PMID:41531219 · one of two readings recorded this

• gastrointestinal bleeding

  no effect, p = 0.083

  GIB (IPTW aHR, 0.73 [0.51–1.04]; p = 0.083)

  PMID:41531219 · one of two readings recorded this

• intracranial hemorrhage

  increases, p = 0.001

  DOAC users had an increased risk of ICH (IPTW aHR, 5.02; 95% CI, 2.66–9.47; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• intracranial hemorrhage

  increases, p = 0.001

  ICH (IPTW aHR, 7.18; 95% CI, 3.82–13.50; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• intracranial hemorrhage

  no effect, p = 0.081

  ICH (IPTW aHR, 0.70 [0.47–1.05]; p = 0.081)

  PMID:41531219 · one of two readings recorded this

• ischemic stroke or systemic embolism composite (IS/SE), time-to-event

  decreases, IPTW aHR 0.55; 95% CI 0.31-1.00 vs no anticoagulation, p = 0.048

  Not recorded as a finding: Composite of ischemic stroke and systemic embolism; stroke-incidence node is stroke only, so near-miss

  Relative to no anticoagulation, both warfarin (IPTW-adjusted hazard ratio [aHR], 0.55; 95% confidence interval [CI], 0.31–1.00; p = 0.048) and DOACs (IPTW aHR, 0.36; 95% CI, 0.19–0.69; p = 0.002) were associated with a lower risk of IS/SE.

  PMID:41531219 · one of two readings recorded this

• ischemic stroke or systemic embolism composite (IS/SE), warfarin vs no anticoagulation

  decreases, IPTW aHR 0.55; 95% CI 0.31-1.00, p = 0.048

  Not recorded as a finding: Composite of ischemic stroke and systemic embolism; stroke-incidence node is stroke only, so no node matches

  Relative to no anticoagulation, both warfarin (IPTW-adjusted hazard ratio [aHR], 0.55; 95% confidence interval [CI], 0.31–1.00; p = 0.048) and DOACs (IPTW aHR, 0.36; 95% CI, 0.19–0.69; p = 0.002) were associated with a lower risk of IS/SE.

  PMID:41531219 · one of two readings recorded this

• ischemic stroke or systemic embolism (IS/SE)

  decreases, p = 0.002

  DOACs (IPTW aHR, 0.36; 95% CI, 0.19–0.69; p = 0.002) were associated with a lower risk of IS/SE

  PMID:41531219 · one of two readings recorded this

• ischemic stroke or systemic embolism (IS/SE)

  decreases, p = 0.048

  Relative to no anticoagulation, both warfarin (IPTW-adjusted hazard ratio [aHR], 0.55; 95% confidence interval [CI], 0.31–1.00; p = 0.048)

  PMID:41531219 · one of two readings recorded this

• ischemic stroke or systemic embolism (IS/SE)

  no effect, p = 0.282

  DOACs had a risk of IS/SE comparable with warfarin (IPTW aHR, 0.66 [0.31–1.40]; p = 0.282)

  PMID:41531219 · one of two readings recorded this

• major bleeding by ISTH criteria (with intracranial hemorrhage and gastrointestinal bleeding), warfarin vs no anticoagulation

  increases, IPTW aHR 2.69; 95% CI 2.06-3.51

  Not recorded as a finding: No major bleeding, intracranial hemorrhage or gastrointestinal bleeding node in the outcome list

  For safety outcomes, warfarin was associated with a higher risk of MB (IPTW aHR, 2.69; 95% CI, 2.06–3.51; p < 0.001) driven by increased risks of both ICH (IPTW aHR, 7.18; 95% CI, 3.82–13.50; p < 0.001) and GIB (IPTW aHR, 1.82; 95% CI, 1.27–2.63; p = 0.001) versus no anticoagulation.

  PMID:41531219 · one of two readings recorded this

• major bleeding, ISTH criteria, time-to-event

  increases, IPTW aHR 2.69; 95% CI 2.06-3.51 vs no anticoagulation, p = 0.001

  Not recorded as a finding: No major-bleeding outcome node in the list

  For safety outcomes, warfarin was associated with a higher risk of MB (IPTW aHR, 2.69; 95% CI, 2.06–3.51; p < 0.001) driven by increased risks of both ICH (IPTW aHR, 7.18; 95% CI, 3.82–13.50; p < 0.001) and GIB (IPTW aHR, 1.82; 95% CI, 1.27–2.63; p = 0.001) versus no anticoagulation.

  PMID:41531219 · one of two readings recorded this

• major bleeding

  increases, p = 0.035

  DOACs were also associated with a higher risk of MB (IPTW aHR, 1.37; 95% CI, 1.02–1.84; p = 0.035)

  PMID:41531219 · one of two readings recorded this

• major bleeding

  increases, p = 0.001

  warfarin was associated with a higher risk of MB (IPTW aHR, 2.69; 95% CI, 2.06–3.51; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• major bleeding

  decreases, p = 0.001

  a significantly lower risk of MB (IPTW aHR, 0.51 [0.40–0.66]; p < 0.001)

  PMID:41531219 · one of two readings recorded this

• major bleeding

  no effect, p = 0.002

  DOACs (aHR, 1.02 [0.52–2.00]; p for interaction = 0.002)

  PMID:41531219 · one of two readings recorded this

• major bleeding

  no effect, p = 0.002

  warfarin (aHR, 1.07 [0.56–2.04]; p for interaction = 0.002)

  PMID:41531219 · one of two readings recorded this

• hemoglobin

  p = 0.038, n = 136

  Hb, g/L | 133.76 ± 14.52 | 128.00 ± 17.73 |.038

  PMID:41553786 · one of two readings recorded this

• age

  p = 0.125, n = 136

  Age, years | 65.86 ± 10.30 | 61.90 ± 15.24 |.125

  PMID:41553786 · one of two readings recorded this

• anti-platelet drug use

  p = 0.001, n = 136

  Anti-platelet drugs, n (%) | 30 (58.8) | 14 (16.5) | <.001

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: combined regression model

  n = 136

  Regression model | 0.900 (0.848–0.952) | 0.843 | 0.835

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: NXT

  n = 136

  NXT | 0.655 (0.561–0.749) | 0.745 | 0.565

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: PDW

  n = 136

  PDW | 0.797 (0.715–0.879) | 0.745 | 0.824

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: PT

  n = 136

  PT | 0.637 (0.541–0.733) | 0.608 | 0.624

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: RAVD

  n = 136

  RAVD | 0.628 (0.534–0.722) | 0.706 | 0.529

  PMID:41553786 · one of two readings recorded this

• AUC for predicting high-quality TTR: RDW

  n = 136

  RDW | 0.645 (0.549–0.742) | 0.549 | 0.718

  PMID:41553786 · one of two readings recorded this

• coronary heart disease prevalence

  p = 0.001, n = 136

  CHD, n (%) | 28 (54.9) | 18 (21.2) | <.001

  PMID:41553786 · one of two readings recorded this

• left ventricular end-systolic diameter

  p = 0.012, n = 136

  LVDs, mm | 31.92 ± 6.14 | 35.37 ± 7.12 |.012

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: ACEI/ARB

  no effect, p = 0.081, n = 136

  ACEI/ARB |.081 | 0.370 (0.121–1.131)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: beta-blockers

  no effect, p = 0.838, n = 136

  Beta-blockers |.838 | 0.895 (0.310–2.587)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: left ventricular end-systolic diameter

  no effect, p = 0.064, n = 136

  LVDs |.064 | 0.928 (0.857–1.004)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: Naoxintong

  unclear, p = 0.022, n = 136

  NXT |.022 | 0.273 (0.090–0.831)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: platelet distribution width

  unclear, p = 0.001, n = 136

  PDW | <.001 | 0.460 (0.337–0.628)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: prothrombin time

  unclear, p = 0.002, n = 136

  PT |.002 | 1.123 (1.044–1.208)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: red cell distribution width

  unclear, p = 0.001, n = 136

  RDW |.001 | 1.774 (1.266–2.486)

  PMID:41553786 · one of two readings recorded this

• multivariable association with TTR: right atrial vertical diameter

  unclear, p = 0.018, n = 136

  RAVD |.018 | 1.054 (1.009–1.102)

  PMID:41553786 · one of two readings recorded this

• Naoxintong (NXT) use

  p = 0.001, n = 136

  NXT, n (%) | 38 (74.5) | 37 (43.5) | <.001

  PMID:41553786 · one of two readings recorded this

• platelet distribution width

  p = 0.001, n = 136

  PDW, % | 14.53 ± 1.80 | 16.55 ± 1.68 | <.001

  PMID:41553786 · one of two readings recorded this

• prothrombin time

  p = 0.004, n = 136

  PT, s | 20.85 ± 7.93 | 16.70 ± 6.29 |.004

  PMID:41553786 · one of two readings recorded this

• red cell distribution width

  p = 0.004, n = 136

  RDW, % | 14.62 ± 2.09 | 13.55 ± 1.33 |.004

  PMID:41553786 · one of two readings recorded this

• right atrial vertical diameter

  p = 0.001, n = 136

  RAVD, mm | 53.43 ± 12.30 | 46.53 ± 9.64 |.001

  PMID:41553786 · one of two readings recorded this

• stroke volume

  p = 0.046, n = 136

  SV, ml | 57.08 ± 13.74 | 62.78 ± 16.22 |.046

  PMID:41553786 · one of two readings recorded this

• time in therapeutic range

  p = 0.001, n = 136

  TTR, % | 75.78 ± 4.83 | 39.99 ± 14.01 | <.001

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: anti-platelet drugs

  increases, p = 0.001, n = 136

  Anti-platelet drugs | <.001 | 7.245(3.256–16.118)

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: coronary heart disease

  increases, p = 0.001, n = 136

  CHD | <.001 | 4.531(2.123–9.673)

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: Naoxintong

  increases, p = 0.001, n = 136

  NXT |.001 | 3.792(1.770–8.124)

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: platelet distribution width

  decreases, p = 0.001, n = 136

  PDW, % | <.001 | 0.529(0.417–0.670)

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: red cell distribution width

  increases, p = 0.002, n = 136

  RDW, % |.002 | 1.414(1.131–1.769)

  PMID:41553786 · one of two readings recorded this

• univariate risk of poor TTR: stroke

  increases, p = 0.037, n = 136

  Stroke |.037 | 2.121(1.046–4.299)

  PMID:41553786 · one of two readings recorded this

• 1-year mRS 0-2 in herniation cases (n)

  1-year mRS 0–2 in herniation cases | 4 (57.1%) | – | 1 (100%) | 3 (100%) | –

  PMID:41765450 · one of two readings recorded this

• 1-year mRS ≥3 in herniation cases (n)

  1-year mRS ≥3 in herniation cases | 3 (42.9%) | – | 0 | 0 | –

  PMID:41765450 · one of two readings recorded this

• age (mean ± SD)

  no effect, p = 0.64

  Age, years (mean ± SD) | 73.9 ± 8.8 | 72.5 ± 10.2 | 74.1 ± 9.1 | 71.8 ± 9.4 | 0.64

  PMID:41765450 · one of two readings recorded this

• bilateral hematoma (n)

  Bilateral hematoma, n (%) | 14 (43.7%) | 12 (31.6%) | 4 (33.3%) | 15 (34.1%)

  PMID:41765450 · one of two readings recorded this

• cerebral herniation (n)

  increases, p = 0.011

  Cerebral herniation, n (%) | 7 (21.9%) | 1 (2.6%) | 2 (16.7%) | 1 (2.3%) | 0.011*

  PMID:41765450 · one of two readings recorded this

• diffuse cortical edema (n)

  increases, p = 0.018

  Diffuse cortical edema, n (%) | 9 (28.1%) | 4 (10.5%) | 3 (25.0%) | 5 (11.4%) | 0.018*

  PMID:41765450 · one of two readings recorded this

• favorable 1-year outcome (mRS 0-2) among all herniation cases

  n = 11

  At one-year follow-up, mRS scores indicated favorable outcomes (mRS 0-2) in 8 of 11 patients (72.7%)

  PMID:41765450 · one of two readings recorded this

• homogeneous subtype (n)

  Homogeneous subtype, n (%) | 8 (25.0%) | 14 (36.8%) | 3 (25.0%) | 19 (43.2%)

  PMID:41765450 · one of two readings recorded this

• laminar subtype (n)

  Laminar subtype, n (%) | 7 (21.9%) | 9 (23.7%) | 3 (25.0%) | 11 (25.0%)

  PMID:41765450 · one of two readings recorded this

• maximal hematoma thickness

  no effect, p = 0.58

  Maximal thickness (mm), mean ± SD | 16.5 ± 5.4 | 16.1 ± 5.2 | 15.9 ± 5.0 | 15.2 ± 4.8 | 0.58

  PMID:41765450 · one of two readings recorded this

• midline shift

  no effect, p = 0.61

  Midline shift (mm), mean ± SD | 5.8 ± 2.3 | 5.5 ± 2.4 | 5.6 ± 2.2 | 5.2 ± 2.1 | 0.61

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (days from reported head trauma to onset of neurological symptoms) in surgically treated chronic subdural hematoma; also cerebral herniation and mRS at discharge

  decreases, mean 23.6 days warfarin vs 46.5 days control, n = 32

  Not recorded as a finding: this platform holds no node for the endpoint

  The mean PTI was significantly shorter in the warfarin group (23.6 ± 9.4 days) compared with aspirin (41.2 ± 15.7 days) and control patients (46.5 ± 18.9 days) (Kruskal-Wallis test, p < 0.001; Bonferroni-adjusted post-hoc, warfarin vs. control p < 0.001, warfarin vs. aspirin p = 0.002).

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), mean

  no effect, p = 0.12, n = 38

  2 | Aspirin | 38 | 41.2 ± 15.7 | 40 (29-52) | 0.12

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), mean

  decreases, p = 0.004, n = 12

  3 | Warfarin + Aspirin | 12 | 28.4 ± 11.1 | 27 (20-36) | 0.004*

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), mean

  decreases, p = 0.001, n = 32

  1 | Warfarin | 32 | 23.6 ± 9.4 | 22 (16-30) | <0.001*

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), mean

  n = 44

  4 | Control | 44 | 46.5 ± 18.9 | 45 (34-59) | Reference

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), median

  no effect, p = 0.12, n = 38

  2 | Aspirin | 38 | 41.2 ± 15.7 | 40 (29-52) | 0.12

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), median

  decreases, p = 0.004, n = 12

  3 | Warfarin + Aspirin | 12 | 28.4 ± 11.1 | 27 (20-36) | 0.004*

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), median

  decreases, p = 0.001, n = 32

  1 | Warfarin | 32 | 23.6 ± 9.4 | 22 (16-30) | <0.001*

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), median

  n = 44

  4 | Control | 44 | 46.5 ± 18.9 | 45 (34-59) | Reference

  PMID:41765450 · one of two readings recorded this

• post-traumatic interval (PTI), post-hoc pairwise

  decreases, p = 0.002

  Bonferroni-adjusted post-hoc, warfarin vs. control p < 0.001, warfarin vs. aspirin p = 0.002

  PMID:41765450 · one of two readings recorded this

• separated subtype (n)

  Separated subtype, n (%) | 8 (25.0%) | 9 (23.7%) | 2 (16.7%) | 8 (18.2%)

  PMID:41765450 · one of two readings recorded this

• sulcal effacement (n)

  increases, p = 0.031

  Sulcal effacement, n (%) | 8 (25.0%) | 3 (7.9%) | 2 (16.7%) | 4 (9.1%) | 0.031*

  PMID:41765450 · one of two readings recorded this

• trabecular subtype (n)

  increases, p = 0.041

  Trabecular subtype, n (%) | 9 (28.1%) | 6 (15.8%) | 4 (33.3%) | 6 (13.6%) | 0.041*

  PMID:41765450 · one of two readings recorded this

• unilateral hematoma (n)

  no effect, p = 0.64

  Unilateral hematoma, n (%) | 18 (56.3%) | 26 (68.4%) | 8 (66.7%) | 29 (65.9%) | 0.64

  PMID:41765450 · one of two readings recorded this

• hemorrhagic recurrence after anticoagulation resumption

  pooled event rate 10.95%

  After anticoagulation resumption, 73 patients experienced hemorrhagic recurrence, corresponding to a pooled event rate of 10.95%, with nonsignificant heterogeneity (I2 = 40.4%).

  PMID:41823243 · one of two readings recorded this

• hemorrhagic recurrence after anticoagulation resumption

  increases, pooled event rate 10.95%

  After anticoagulation resumption, 73 patients experienced hemorrhagic recurrence, corresponding to a pooled event rate of 10.95%, with nonsignificant heterogeneity (I2 = 40.4%).

  PMID:41823243 · one of two readings recorded this

• ischemic stroke incidence while off anticoagulation after intracranial hemorrhage in mechanical heart valve patients, pooled event rate

  increases, pooled event rate 5.23%, 95% CI, 3.80-7.20%

  Not recorded as a finding: the comparison was against another active treatment

  While off anticoagulation, 32 patients developed ischemic stroke, with a pooled event rate of 5.23% (95% CI, 3.80-7.20%) and negligible heterogeneity (I2 = 0%).

  PMID:41823243 · one of two readings recorded this

• ischemic stroke while off anticoagulation, after intracranial hemorrhage in patients with mechanical heart valves, pooled event rate

  pooled event rate 5.23% (95% CI, 3.80-7.20%)

  Not recorded as a finding: the comparison was against another active treatment

  While off anticoagulation, 32 patients developed ischemic stroke, with a pooled event rate of 5.23% (95% CI, 3.80-7.20%) and negligible heterogeneity (I2 = 0%).

  PMID:41823243 · one of two readings recorded this

• ischemic stroke while off anticoagulation

  pooled event rate 5.23% (95% CI, 3.80-7.20%)

  While off anticoagulation, 32 patients developed ischemic stroke, with a pooled event rate of 5.23% (95% CI, 3.80-7.20%) and negligible heterogeneity (I2 = 0%).

  PMID:41823243 · one of two readings recorded this

• ischemic stroke while off anticoagulation

  increases, pooled event rate 5.23%, 95% CI, 3.80-7.20%

  While off anticoagulation, 32 patients developed ischemic stroke, with a pooled event rate of 5.23% (95% CI, 3.80-7.20%) and negligible heterogeneity (I2 = 0%).

  PMID:41823243 · one of two readings recorded this

• 30% or greater decline in eGFR (CKD-EPI), doubling of serum creatinine, acute kidney injury (KDIGO), ischemic stroke and systemic embolism; NOACs versus warfarin

  NOAC vs warfarin aHR 0.67 for 30% eGFR decline

  Not recorded as a finding: the comparison was against another active treatment

  Compared with the warfarin group, the NOAC group was associated with a lower risk of a ≥30% decline in the eGFR, with an aHR of 0.67 (95% CI 0.45–1.00, p = 0.050) after adjusting for all covariates using the doubly robust approach.

  PMID:41901613 · one of two readings recorded this

• acute kidney injury, adjusted hazard ratio

  no effect, p = 0.169, n = 1456

  AKI (aHR 0.69, 95% CI 0.41–1.17, p = 0.169)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, adjusted hazard ratio

  decreases, p = 0.026

  dabigatran (aHR 0.37, 95% CI 0.16–0.89, p = 0.026)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, adjusted hazard ratio

  decreases, p = 0.029

  edoxaban (aHR 0.32, 95% CI 0.11–0.89, p = 0.029)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, adjusted hazard ratio

  decreases, p = 0.05, n = 1456

  the NOAC group was associated with a lower risk of a ≥30% decline in the eGFR, with an aHR of 0.67 (95% CI 0.45–1.00, p = 0.050)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, multivariable logistic regression: age 75 years or older

  increases, p = 0.001, n = 1456

  age ≥ 75 years (OR 1.72, 95% CI 1.28–2.32, p < 0.001)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, multivariable logistic regression: diabetes mellitus

  increases, p = 0.002, n = 1456

  diabetes mellitus (OR 1.59, 95% CI 1.18–2.13, p = 0.002)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, multivariable logistic regression: hypertension

  increases, p = 0.018, n = 1456

  hypertension (OR 1.82, 95% CI 1.11–2.99, p = 0.018)

  PMID:41901613 · one of two readings recorded this

• at least 30% eGFR decline, multivariable logistic regression: NOAC use

  decreases, p = 0.014, n = 1456

  NOAC use (OR 0.70, 95% CI 0.52–0.93, p = 0.014)

  PMID:41901613 · one of two readings recorded this

• doubling of serum creatinine, adjusted hazard ratio

  no effect, p = 0.373, n = 1456

  doubling of SCr (aHR 0.64, 95% CI 0.24–1.72, p = 0.373)

  PMID:41901613 · one of two readings recorded this

• heart failure prevalence at baseline before IPTW

  p = 0.002, n = 1456

  had a higher prevalence of heart failure (27.1% vs. 15.5%, p = 0.002)

  PMID:41901613 · one of two readings recorded this

• ischemic stroke and systemic embolism, adjusted hazard ratio

  no effect, p = 0.084, n = 1456

  aHR 0.49, 95% CI 0.22–1.10, p = 0.084

  PMID:41901613 · one of two readings recorded this

• ischemic stroke and systemic embolism incidence rate

  decreases, n = 1456

  the incidence rate of ischemic stroke and SEE was 1.87 per 100 person-year and 3.02 per 100 person-year in the NOAC and warfarin group, respectively

  PMID:41901613 · one of two readings recorded this

• ischemic stroke and systemic embolism, unadjusted hazard ratio

  decreases, p = 0.015, n = 1456

  Unadjusted HR 0.45, 95% CI 0.24–0.85, p = 0.015

  PMID:41901613 · one of two readings recorded this

• male sex at baseline before IPTW

  p = 0.009, n = 1456

  the NOAC group was more likely to be male (59.7% vs. 53.0%, p = 0.009)

  PMID:41901613 · one of two readings recorded this

• median body weight at baseline before IPTW

  p = 0.001, n = 1456

  had higher median body weight (67.5 kg vs. 64 kg, p < 0.001)

  PMID:41901613 · one of two readings recorded this

• patients with at least 30% eGFR decline

  decreases, n = 1456

  a ≥30% decline in the eGFR occurred in 98 and 143 patients who received NOACs (14.1%) and warfarin (18.8%), respectively

  PMID:41901613 · one of two readings recorded this

• developmental delay on Denver II screening

  no effect, p = 0.7, n = 32

  Developmental delay on Denver II screening was identified in 2 of 32 children (p = 0.7)

  PMID:41957566 · one of two readings recorded this

• growth parameters below the 3rd percentile

  no effect, n = 32

  No child had growth parameters below the 3rd percentile

  PMID:41957566 · one of two readings recorded this

• median age at last follow-up

  n = 32

  The median age at last follow-up was 61.5 months (range 9-168)

  PMID:41957566 · one of two readings recorded this

• minor neonatal echocardiographic findings

  n = 32

  Minor neonatal echocardiographic findings (e.g., patent ductus arteriosus or patent foramen ovale) were observed in 10 children (31%)

  PMID:41957566 · one of two readings recorded this

• overall prematurity rate

  n = 32

  The overall rate of prematurity was 19%

  PMID:41957566 · one of two readings recorded this

• prematurity rate and Denver II developmental delay in children after first-trimester exposure to low-dose warfarin (2.5 or 4 mg/day) plus enoxaparin versus enoxaparin alone

  p = 0.6

  Not recorded as a finding: a direction is stated and the estimate does not support it

  Although higher in children receiving enoxaparin plus warfarin (2.5 mg or 4 mg/day) compared with those receiving enoxaparin alone, the difference was not statistically significant (p = 0.6).

  PMID:41957566 · one of two readings recorded this

• prematurity rate in children after first-trimester exposure to low-dose warfarin plus enoxaparin versus enoxaparin alone (abstract only)

  prematurity rate higher with enoxaparin plus warfarin than enoxaparin alone, not significant, p = 0.6, n = 32

  Not recorded as a finding: a direction is stated and the estimate does not support it

  Although higher in children receiving enoxaparin plus warfarin (2.5 mg or 4 mg/day) compared with those receiving enoxaparin alone, the difference was not statistically significant (p = 0.6).

  PMID:41957566 · one of two readings recorded this

• prematurity, warfarin plus enoxaparin vs enoxaparin alone

  no effect, p = 0.6, n = 32

  Although higher in children receiving enoxaparin plus warfarin (2.5 mg or 4 mg/day) compared with those receiving enoxaparin alone, the difference was not statistically significant (p = 0.6)

  PMID:41957566 · one of two readings recorded this

• mean age of patients with SEH reports

  The mean age of patients with SEH reports was notably lower for Warfarin (62 years) compared to the DOACs, where the mean age was 75–76 years

  PMID:42062621 · one of two readings recorded this

• proportional reporting ratio, spinal epidural hematoma/hemorrhage

  increases, n = 25

  Apixaban | 0.01 | 66.703 | 25 | 387 | 184,022 | 13,625,800 | 4.55 (3.04–6.82) | 4.78 (3.19–7.17) | 4.78 (3.19–7.17) | YES

  PMID:42062621 · one of two readings recorded this

• proportional reporting ratio, spinal epidural hematoma/hemorrhage

  increases, n = 7

  Dabigatran | 0.02 | 22.506 | 7 | 405 | 41,400 | 13,768,400 | 5.67 (2.69–12) | 5.75 (2.72–12.1) | 5.75 (2.72–12.1) | YES

  PMID:42062621 · one of two readings recorded this

• proportional reporting ratio, spinal epidural hematoma/hemorrhage

  increases, n = 28

  Rivaroxaban | 0.02 | 138.495 | 28 | 384 | 123,419 | 13,686,400 | 7.6 (5.18–11.1) | 8.08 (5.51–11.9) | 8.09 (5.51–11.9) | YES

  PMID:42062621 · one of two readings recorded this

• proportional reporting ratio, spinal epidural hematoma/hemorrhage

  increases, n = 83

  Warfarin | 0.07 | 1777.99 | 83 | 329 | 118,487 | 13,691,300 | 23.5 (18.5–29.7) | 29.1 (22.9–37.1) | 29.2 (22.9–37.1) | YES

  PMID:42062621 · one of two readings recorded this

• reporting odds ratio, spinal epidural hematoma/hemorrhage

  increases, n = 25

  Apixaban | 0.01 | 66.703 | 25 | 387 | 184,022 | 13,625,800 | 4.55 (3.04–6.82) | 4.78 (3.19–7.17) | 4.78 (3.19–7.17) | YES

  PMID:42062621 · one of two readings recorded this

• reporting odds ratio, spinal epidural hematoma/hemorrhage

  increases, n = 7

  Dabigatran | 0.02 | 22.506 | 7 | 405 | 41,400 | 13,768,400 | 5.67 (2.69–12) | 5.75 (2.72–12.1) | 5.75 (2.72–12.1) | YES

  PMID:42062621 · one of two readings recorded this

• reporting odds ratio, spinal epidural hematoma/hemorrhage

  increases, n = 28

  Rivaroxaban | 0.02 | 138.495 | 28 | 384 | 123,419 | 13,686,400 | 7.6 (5.18–11.1) | 8.08 (5.51–11.9) | 8.09 (5.51–11.9) | YES

  PMID:42062621 · one of two readings recorded this

• reporting odds ratio, spinal epidural hematoma/hemorrhage

  increases, n = 83

  Warfarin | 0.07 | 1777.99 | 83 | 329 | 118,487 | 13,691,300 | 23.5 (18.5–29.7) | 29.1 (22.9–37.1) | 29.2 (22.9–37.1) | YES

  PMID:42062621 · one of two readings recorded this

• mean INR change

  no effect, p = 0.79, n = 1021

  the mean INR value remained unchanged (95% CI, −0.02 to 0.03; p = 0.79)

  PMID:42115581 · one of two readings recorded this

• mean INR recheck interval change

  decreases, p = 0.049, n = 1021

  the mean INR recheck interval decreased by 0.7 days (95% CI, −1.4 to 0.0; p = 0.049)

  PMID:42115581 · one of two readings recorded this

• time above therapeutic range change

  increases, p = 0.04, n = 1021

  time above the therapeutic range increased by 1.3% (95% CI, 0.1 to 2.6; p = 0.04)

  PMID:42115581 · one of two readings recorded this

• time below therapeutic range change

  no effect, p = 0.25, n = 1021

  Time below the therapeutic range increased by 0.8% (95% CI, −0.5 to 2.1; p = 0.25)

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  decreases, p = 0.02

  patients aged 75 and older were the only age group with a statistically significant mean TTR decrease of −4.8% (95% CI, −8.9 to −0.8; p = 0.02)

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  no effect, p = 0.78

  whereas in females it was −0.3% (95% CI, −2.5 to 1.9; p = 0.78)

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  decreases, p = 0.01

  The mean TTR decrease in males was −3.1% (95% CI, −5.3 to −0.9; p = 0.01)

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  decreases, p = 0.01

  Non-Hispanic or Latino patients showed a mean decrease in TTR of −2.3% (95% CI, −4.0 to −0.6; p = 0.01

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  decreases, p = 0.02

  the mean TTR decrease in White patients was −2.3% (95% CI, −4.1 to −0.4; p = 0.02)

  PMID:42115581 · one of two readings recorded this

• time in therapeutic range change

  decreases, p = 0.01, n = 1021

  Following GLP-1 RA initiation, TTR decreased by 2.1% (95% CI, −3.7 to −0.6; p = 0.01)

  PMID:42115581 · one of two readings recorded this

• within-patient INR standard deviation

  no effect, p = 0.051, n = 1021

  the within-patient INR standard deviation increased from 0.63 in the pre-index period to 0.66 in the post-index period (95% CI, 0.00 to 0.05; p = 0.051)

  PMID:42115581 · one of two readings recorded this

• cardiovascular events including myocardial infarction and systemic embolism (high dose groups)

  no effect, RR 0.96, 95% CI: 0.83 to 1.11, p = 0.58

  The pooled risk estimate (RR = 0.96, 95% CI: 0.83 to 1.11; p = 0.58) was close to unity, and the confidence interval spanned 1, indicating no clear superiority over Warfarin.

  PMID:42415975 · one of two readings recorded this

• cardiovascular events (myocardial infarction and systemic embolism)

  no effect, RR 0.96, 95% CI 0.83-1.11, p = 0.58

  The pooled risk estimate (RR = 0.96, 95% CI: 0.83 to 1.11; p = 0.58) was close to unity, and the confidence interval spanned 1, indicating no clear superiority over Warfarin.

  PMID:42415975 · one of two readings recorded this

• major bleeding (high dose groups)

  no effect, RR 0.89, 95% CI: 0.75–1.04, p = 0.14

  The high-dose DOACs demonstrated a non-significant reduction in major bleeding risk compared to warfarin, with a pooled risk ratio of 0.89 (95% CI: 0.75–1.04; p=0.14).

  PMID:42415975 · one of two readings recorded this

• major bleeding

  no effect

  The lack of statistical significance suggests comparable bleeding risks between the two treatments.

  PMID:42415975 · one of two readings recorded this

• minor bleeding (high dose groups)

  no effect, RR 0.92, 95% CI: 0.76–1.11, p = 0.37

  No significant difference was found in minor bleeding rates between high-dose DOACs and warfarin (RR: 0.92, 95% CI: 0.76–1.11; p=0.37).

  PMID:42415975 · one of two readings recorded this

• minor bleeding

  no effect, RR 0.92, 95% CI 0.76-1.11, p = 0.37

  No significant difference was found in minor bleeding rates between high-dose DOACs and warfarin (RR: 0.92, 95% CI: 0.76–1.11; p=0.37).

  PMID:42415975 · one of two readings recorded this

• stroke incidence, pooled risk ratio (high-dose DOACs vs warfarin, randomized controlled trials)

  RR 0.81, 95% CI 0.74-0.89

  Not recorded as a finding: the comparison was against another active treatment

  DOACs were favored by the pooled risk ratio of 0.81 (95% CI: 0.74 to 0.89; p<0.00001).

  PMID:42415975 · one of two readings recorded this

• stroke occurrence (high dose groups)

  decreases, RR 0.81, 95% CI: 0.74 to 0.89

  DOACs were favored by the pooled risk ratio of 0.81 (95% CI: 0.74 to 0.89; p<0.00001).

  PMID:42415975 · one of two readings recorded this

• stroke occurrence in atrial fibrillation, pooled risk ratio (high-dose DOAC vs warfarin)

  decreases, RR 0.81, 95% CI: 0.74 to 0.89

  Not recorded as a finding: the comparison was against another active treatment

  DOACs were favored by the pooled risk ratio of 0.81 (95% CI: 0.74 to 0.89; p<0.00001).

  PMID:42415975 · one of two readings recorded this

• stroke

  RR 0.81, 95% CI 0.74-0.89

  DOACs were favored by the pooled risk ratio of 0.81 (95% CI: 0.74 to 0.89; p<0.00001).

  PMID:42415975 · one of two readings recorded this

• adjusted time in therapeutic range

  increases, p = 0.001, n = 5903

  Self-testers had higher adjusted time in therapeutic range (TTR; 65.3% vs 59.8%; P < .001)

  PMID:42422772 · one of two readings recorded this

• adjusted time in therapeutic range

  increases, p = 0.0018

  Among Black patients, self-testers had higher TTR (58.8% vs 55.4%; P = .0018)

  PMID:42422772 · one of two readings recorded this

• adjusted time in therapeutic range

  increases, p = 0.0001

  Among White patients, self-testers had higher adjusted TTR (68.1% vs 61.3%, P < .0001)

  PMID:42422772 · one of two readings recorded this

• major bleeding rate

  decreases, p = 0.014

  fewer major (3.4 vs 4.9 per 100 patient-years, P = .014)

  PMID:42422772 · one of two readings recorded this

• nonmajor bleeding rate

  decreases, p = 0.0001, n = 5903

  lower nonmajor bleeding rates (20.9 vs 29.9 per 100 patient-years; P < .0001)

  PMID:42422772 · one of two readings recorded this

• nonmajor bleeding rate

  decreases, p = 0.024

  fewer nonmajor bleeds (23.1 vs 33.1 per 100 patient-years; P = .024)

  PMID:42422772 · one of two readings recorded this

The whole record — 262 rows